Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 17;3:165-72.
doi: 10.2147/dmsott.s7493.

Critical Appraisal of Once-Weekly Formulation of Exenatide in the Control of Type 2 Diabetes Mellitus

Affiliations
Free PMC article

Critical Appraisal of Once-Weekly Formulation of Exenatide in the Control of Type 2 Diabetes Mellitus

Jason Seewoodhary et al. Diabetes Metab Syndr Obes. .
Free PMC article

Abstract

Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of <7% in >75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.

Keywords: GLP-1 mimetic; HbA1c; weight loss.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787. - PubMed
    1. Zimmet P, Lefèbvre P. The global NIDDM epidemic: treating the disease and ignoring the symptom [Editorial] Diabetologia. 1996;39:1247–1248. - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care. 2009;32 (Suppl 1):S13–S61. - PMC - PubMed
    1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin- dependent diabetes mellitus. N Engl J Med. 1993;329:977–986. - PubMed
    1. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412. - PMC - PubMed

LinkOut - more resources

Feedback